SMS Pharma Q2FY27: Revenue Soars 30% to ₹316 Cr, PAT Jumps 57% to ₹40 Cr
SMS Pharmaceuticals Limited reported a 30% YoY increase in Q2FY27 revenue to ₹316 crore and a 57% YoY jump in PAT to ₹40 crore. H1FY27 revenue rose 19% to ₹523 crore. The company is on track for 10 DMF/CEP filings in FY27 and its ₹280 crore capex program by FY27. The Peptides R&D facility is operational.
The significant growth in key financial metrics like revenue and profit, coupled with strategic advancements in R&D and capital expenditure, are material positive developments for the company's stakeholders, including investors and the market.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, exceeding previous guidance and demonstrating positive operational and financial performance. The progress on DMF filings, capex, and R&D facilities also indicates a positive outlook.
SMS Pharmaceuticals Limited has announced its financial results for the second quarter and half year ended September 30, 2026. The company reported a significant 30% year-on-year increase in revenue from operations, reaching ₹316 crore for Q2FY27, driven by strong volume growth and improved price realization. Gross margin increased to 35%, attributed to the benefits of backward integration, and EBITDA margin expanded by 145 basis points to 21% due to operating leverage.
Profit After Tax (PAT) saw a substantial rise of 57% year-on-year, amounting to ₹40 crore. For the first half of FY27 (H1FY27), revenue from operations grew by 19% to ₹523 crore, with EBITDA up 24% to ₹109 crore and PAT increasing by 36% to ₹60 crore.
The company has completed 6 Drug Master File (DMF)/Certificate of Suitability to the European Pharmacopoeia (CEP) filings in FY27 to date and is on track to meet its full-year target of 10 DMF/CEP filings. The ₹280 crore capital expenditure program is progressing as planned for completion by FY27. Furthermore, the Peptides R&D facility is now fully operational, with pilot scale production targeted for Q4FY27 and initial CRO revenue anticipated in Q2FY28.
The investor presentation also highlighted the company's strategic focus on R&D, backward integration, and capacity expansion to drive future growth and margin expansion. The company's manufacturing facilities in Hyderabad and Vizag are globally compliant and have received approvals from regulatory bodies like USFDA and EUGMP. SMS Pharmaceuticals Limited has a diversified portfolio across various therapeutic areas and a strong presence in regulated markets, with 88% of its revenue originating from these markets.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.